News tagged with bortezomib
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer May 01, 2013 | not rated yet | 0
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...
Cancer Apr 02, 2013 | 4 / 5 (1) | 0
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to ...
Cancer Apr 01, 2013 | not rated yet | 0
Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.
Cancer Feb 19, 2013 | 1 / 5 (1) | 0
Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often ...
Cancer Jan 03, 2013 | 5 / 5 (2) | 0 |
(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...
Cancer Sep 05, 2012 | not rated yet | 0 |
(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from ...
Cancer Aug 08, 2012 | not rated yet | 0
(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy ...
Cancer Jul 23, 2012 | not rated yet | 0
(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.
Cancer Jul 20, 2012 | not rated yet | 0
Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devast ...
Cancer Feb 13, 2012 | not rated yet | 0
A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.
Medications Sep 22, 2011 | 5 / 5 (1) | 0 |
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving ...
Cancer Jun 02, 2011 | not rated yet | 0 |
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
For more information about Bortezomib, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.